Pharmaceuticals, Biotechnology and Life Sciences
Novartis has secured its crizanlizumab (SEG101) Breakthrough Therapy designation US Food and Drug Administration (FDA), for the prevention of vaso-occlusive crises (VOCs) in patients of all genotypes with sickle cell disease (SCD).
In addition to yesterda’s announcement of moving to buy CAR-T cell producer CellforCure from LFB, Novartis today announced that it acquired another biopharmaceutical company focused on developing radioligand and CAR-T therapies for cancer treatment, the US based Endocyte, Inc.
Novartis today revealed its offer to buy a French contract development and manufacturing organizations (CDMO) producing cell and gene therapies in Europe, Cellforcure.
Novartis announced today that Susanne Schaffert, Ph.D., currently President, Advanced Accelerator Applications (AAA), a Novartis company, has been appointed CEO Novartis Oncology, and will join the Executive Committee in the beginning of new year. Liz Barrett will be stepping down as CEO of Novartis Oncology.
Novartis’s Biologics License Application (BLA) for Zolgensma, designed to tackle the genetic root cause of spinal muscular atrophy (SMA) Type 1, a deadly neuromuscular disease, was accepted by the U.S. Food and Drug Administration (FDA).
Novartis’s Gilenya became the first and only oral disease-modifying treatment for young patients with relapsing-remitting forms of multiple sclerosis (RRMS),…
Novartis’s eye care division Alcon, on Tuesday has its first Capital Markets Day for investors and analysts as a tax-neutral,…
Novartis’ Luxturna, a one-time gene therapy for the treatment of patients with vision loss due to a genetic mutation, developed…
Novartis’s division Sandoz, and Pear Therapeutics, have launched reSET for patients with Substance Use Disorder (SUD), which is th efirst…
Novartis has signed a renewed memorandum of understanding with the World Health Organization (WHO) to extend its drug donation for Egaten…